Physician profile
Eric C Schertzer
NPI 1689762338
$25,616.62
in general payments reported to CMS, 2019-2025
57 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 96% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,481 · 2020: $3,069 · 2021: $9,871 · 2022: $3,303 · 2023: $1,906 · 2024: $2,501 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,787 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,786.62 |
| Education | $105.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,493.36 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $3,123.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $3,094.59 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $2,048.96 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,273.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $901.59 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $573.85 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $473.95 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $469.98 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Corium, LLC | $456.11 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $454.09 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $452.34 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $413.97 | 2019-2022 | |
| Exact Sciences Corporation | $281.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $280.79 | 2023-2024 | Veozah |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schertzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.